Successful treatment with dupilumab for mucus plugs in severe asthma
Respirology Case Reports, 2023 A 29‐year‐old man presented to our hospital with severe eosinophilic asthma. He needed a short OCS burst for exacerbation of asthma once every 1 or 2 months, although he used a high dose of inhaled corticosteroids and a long‐acting beta‐2 agonists. Chest
Moriyasu Anai +7 more
doaj +1 more source
Pharmaceutics, 2023 The role of type 2 inflammation has been progressively associated with many diseases, including severe asthma, atopic dermatitis, nasal polyposis, eosinophilic granulomatosis with polyangiitis, and, recently, eosinophilic esophagitis.
Diego Bagnasco +7 more
doaj +1 more source
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma : results from two phase 3, randomised, double-blind, placebo-controlled trials [PDF]
, 2020 BACKGROUND: Reslizumab 3 mg/kg administered intravenously is approved for the treatment of severe eosinophilic asthma. We assessed the safety and efficacy of subcutaneous reslizumab 110 mg in two trials in patients with uncontrolled severe asthma and ...
Adir, Yochai +13 more
core +1 more source
PLoS ONE, 2021 PurposeTo characterize the clinical phenotypes of severe eosinophilic asthma based on early responsiveness to benralizumab in terms of forced expiratory volume in 1 second (FEV1) improvement.Patients and methodsSixty-four participants diagnosed with ...
Hideyasu Yamada +10 more
doaj +1 more source
Severe eosinophilic bronchial asthma: new therapeutic options
Медицинский совет, 2018 Eosinophilic asthma is a common phenotype of severe asthma, occurring in at least half of patients. In recent years, there have been significant changes in the approaches to the treatment of severe bronchial asthma and, above all, eosinophilic asthma ...
N. M. Nenasheva
doaj +1 more source
Diagnosis and management of eosinophilic asthma: a US perspective. [PDF]
, 2014 Eosinophilic asthma is now recognized as an important subphenotype of asthma based on the pattern of inflammatory cellular infiltrate in the airway. Eosinophilic asthma can be associated with increased asthma severity, atopy, late-onset disease, and ...
Doherty, Taylor A, Walford, Hannah H
core +1 more source
Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
Journal of Clinical Medicine, 2023 Background: Mepolizumab and benralizumab are monoclonal antibodies directed against anti-IL-5 and anti-IL5R, respectively, and their use reduces the exacerbation rate and maintains oral corticosteroid requirements in severe eosinophilic asthma.
G. Scioscia +14 more
semanticscholar +1 more source
Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? [PDF]
, 2014 The authors acknowledge the medical writing assistance received from Sam Yarwood, PhD, of Complete HealthVizion, in the form of literature searches and preparation and revision of the draft manuscript.Peer reviewedPublisher ...
Fromer, Leonard +4 more
core +21 more sources
Monoclonal antibodies in type 2 asthma : a systematic review and network meta-analysis [PDF]
, 2019 Since novel treatments to target eosinophilic inflammation in Type 2 asthma are emerging, we aimed to evaluate and meta-analyze the efficacy of monoclonal antibodies to reduce exacerbation rate.
De Feyter, Silke +4 more
core +1 more source
Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils [PDF]
, 2017 INTRODUCTION: Asthma with adult onset and elevated blood eosinophils is a difficult-to-treat subgroup. This post hoc analysis evaluated reslizumab, an anti-interleukin-5 monoclonal antibody, in patients with late-onset eosinophilic asthma.
Brusselle, Guy +3 more
core +2 more sources